Fraser Claire
SEC insider (Form 3/4/5 filer). CIK 0001382031. Director at Seres Therapeutics, Inc. (MCRB) and 2 other issuers. 7 reported Form 4/5 transactions since Sep 2024; latest on Jul 8, 2026. Located in CAMBRIDGE, MA.
Companies Fraser Claire has filed insider reports for
- Seres Therapeutics, Inc. (MCRB): Director
- WATERS CORP /DE/ (WAT): Director
- BECTON DICKINSON & CO (BDX): Director
Fraser Claire
CIK: 0001382031
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jul 8, 2026MCRB
Seres Therapeutics, Inc.
AwardDirectStock Option (right to buy)
6.5K shares- - Feb 25, 2026WAT
WATERS CORP /DE/
AwardDirect358 shares- - Sep 10, 2025BDX
BECTON DICKINSON & CO
SaleDirect917 shares at avg. $187.50$172K - Aug 8, 2025BDX
BECTON DICKINSON & CO
SaleDirect863 shares at avg. $192.30$166K - Jul 1, 2025MCRB
Seres Therapeutics, Inc.
AwardDirectStock Option (right to buy)
6.5K shares- - Apr 10, 2025MCRB
Seres Therapeutics, Inc.
AwardDirectStock Option (right to buy)
100K shares- - Jan 28, 2025BDX
BECTON DICKINSON & CO
AwardDirect930 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 8, 2026 |  MCRB Seres Therapeutics, Inc. | Award Stock Option (right to buy) | 6,500 | - | - | Direct |
| Feb 25, 2026 |  WAT WATERS CORP /DE/ | Award | 358 | - | $0 | Direct |
| Sep 10, 2025 |  BDX BECTON DICKINSON & CO | Sale | 917 | $187.50 | $171,938 | Direct |
| Aug 8, 2025 | BDX BECTON DICKINSON & CO | Sale | 863 | $192.30 | $165,955 | Direct |
| Jul 1, 2025 | MCRB Seres Therapeutics, Inc. | Award Stock Option (right to buy) | 6,452 | - | - | Direct |
| Apr 10, 2025 | MCRB Seres Therapeutics, Inc. | Award Stock Option (right to buy) | 100,000 | - | - | Direct |
| Jan 28, 2025 | BDX BECTON DICKINSON & CO | Award | 930 | - | $0 | Direct |
1-7 of 7 transactions